British pharmaceutical company Synairgen claimed its new respiratory treatment for coronavirus reduced the number of Covid-19 hospital patients requiring intensive care in a clinical trial.
The company said its nebulizer treatment reduced the risk of developing severe disease in patients by 79% compared to those who received placebo in the initial trials, and that patients who received the treatment “had more than twice the more likely to be cured (defined as “no limitation in activities”. or “no clinical or virologic evidence of infection”) during the treatment period compared to those given a placebo, “Synairgen said.
The study has not yet been published in a peer-reviewed journal, nor the full data made public, however.
The drug, SNG001, is a formulation of a natural antiviral protein called interferon beta that is inhaled directly into the lungs, in the hope of stimulating an immune response. Treatment aims to prevent infected patients who are deteriorating from needing oxygen to be placed on a ventilator.
“This assessment of SNG001 in Covid-19 patients could signal a major breakthrough in the treatment of Covid-19 hospital patients,” said Synairgen CEO Richard Marsden.
“Our efforts are now focused on working with regulators and other key groups to advance this potential Covid-19 treatment as quickly as possible.”
The double-blind, placebo-controlled trial studied 101 patients at nine specialist hospital sites in the UK between March 30 and May 27.
The trial’s chief investigator, Professor Tom Wilkinson, hailed a “capital coordinated effort” and said the results confirmed the researchers’ belief that interferon beta has “enormous potential as an inhaled drug for be able to restore the lung’s immune response, improve protection, accelerate recovery. and counter the impact. “
Synairgen will now have to present results to regulators around the world and hopes to track antiviral drug remdesivir by receiving emergency approval from the UK government.
UK investment bank Finncap tripled Synairgen’s target price from 120 pence per share to 360 pence per share in response to the news.